Biotech

Biotech & Healthcare News

Biotech Healthcare Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 27.06.2022.

Medicine
Pharmacology
Drug development
Learning
Recessive dystrophic epidermolysis bullosa
Pneumococcal conjugate vaccine

@matthewherper shared
On Jun 21, 2022
RT @GideonGil: We’re thrilled to welcome ⁦@ambaReports⁩ ⁦@brittanytrang⁩ & we’re grateful to ⁦@KSJatMIT⁩ for being great partners & ⁦@cziscience⁩ for your support: STAT announces 2022-2023 recipients of Sharon Begley Science Reporting Fellowship https://t.co/S02HjPZJA6
Open
STAT announces 2022-2023 recipients of Sharon Begley Science Reporting Fellowship

STAT announces 2022-2023 recipients of Sharon Begley Science Reporting Fellowship

STAT announced Ambar Castillo and Brittany Trang are the 2022-2023 recipients of the Sharon Begley Science Reporting Fellowship.

@Biotechnology shared
On Jun 23, 2022
Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome https://t.co/dA9cG13y12 https://t.co/nN55TRXmV1
Open
Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Global Roundup: Olink Publishes Updated Genetic Atlas of the Plasma Proteome

Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.

@ldtimmerman shared
On Jun 22, 2022
Why Kymab, the UK-based antibody drug developer, Agreed to be Acquired by Sanofi for $1.1B upfront. Go behind the scenes with @VikasGoyalVGVC. https://t.co/CoSgGx2jJL
Open
Why Kymab Agreed to be Acquired by Sanofi

Why Kymab Agreed to be Acquired by Sanofi

UK-based Kymab made headlines back in January 2021. Sanofi agreed to acquire the antibody drug developer for $1.1 billion upfront, plus $350 million in potential milestones. The main ...

@JNJInnovation shared
On Jun 22, 2022
RT @JNJGlobalHealth: Outbreaks of flaviviruses, like #dengue and Zika, are occurring more frequently and spreading beyond tropical areas where they’ve traditionally thrived. We launched the #JNJ Satellite Center at @DukeNUS in Singapore to take on these threats. Learn more ➡️ https://t.co/RvKLxJlbWz https://t.co/B0LmYol7r9
Open
Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research

Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research

The new Satellite Center will work to accelerate discovery research against flaviviruses, including dengue, which impacts 400 million people each year This effort will build on Johnson & ...

@DrugInfoAssn shared
On Jun 24, 2022
Register at the 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐂𝐨𝐦𝐦𝐮𝐧𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 and get insights into how to improve customers’ experience and successfully partner with suppliers. Registration Link ➡️ https://t.co/yUxR0Tww38 #MedInfo22 https://t.co/LojW2ISGO5
Open
Medical Information and Communications Conference

Medical Information and Communications Conference

Medical Information and Communications Conference

@Biotechnology shared
On Jun 21, 2022
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development https://t.co/EX5IZtgi6v https://t.co/cfSqHoygL4
Open
Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development

Merck, Emergent, Affinivax and Ocugen Level Up in Vaccine Development

​​​​​​​The week started with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax, and Ocugen. 

@BIODeutschland shared
On Jun 23, 2022
Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022 https://t.co/dOpziX9TQ7
Open
Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

Vivoryon Therapeutics N.V. Reports Outcome of Annual General Meeting 2022

All proposed resolutions approved All existing members re-appointed Board strengthened and diversified HALLE (SAALE) / MUNICH, GERMANY, June 22, 2022 – Vivoryon Therapeutics N.V. (Euronext ...

@Prof_ChrisMason shared
On Jun 22, 2022
RT @KrystalBiotech: #NEWS: Krystal Biotech announced today the submission of a Biologics License Application (BLA) to the U.S. FDA seeking approval of B-VEC for the treatment of patients w/ dystrophic epidermolysis bullosa (DEB).  Read the full release here: https://t.co/KtHEgje7la https://t.co/OduGPxG2AC
Open
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis Bullosa

The Investor Relations website contains information about Krystal Biotech's business for stockholders, potential investors, and financial analysts.